Zydus Lifesciences (ZYDUSLIFE) Q2 25/26 earnings summary

Executive summary

• Achieved robust financial performance in Q2 FY26, with consolidated revenues from operations reaching INR 61.2 billion, up 17% year-on-year, and net profit at INR 12.6 billion, a 38% YoY increase, driven by strong growth across India, US, and international markets.

• Completed strategic acquisitions of ComfortClick (UK-based VMS platform) and full ownership of Amplitude Surgical, enhancing international and medtech presence.

• Board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, following Audit Committee recommendations.

• Continued focus on innovation, specialty portfolio expansion, and global market reach, especially in the US, Europe, and emerging markets.

• Consumer Wellness made its first international acquisition, expanding presence in UK, EU, and US.

Financial highlights

• Consolidated revenues reached INR 61.2 billion, up 17% year-on-year; EBITDA margin improved to 32.9% (up 500 bps YoY); EBITDA at INR 20.2 billion, up 38% YoY; net profit for the quarter was INR 12.6 billion, up 38% YoY.

• Consumer wellness revenues grew 31% YoY to INR 6.4 billion; international formulations up 39% YoY to INR 7.5 billion.

• R&D expenses were INR 4.82 billion, 7.9% of revenues; net gain on foreign currency transactions was INR 4.14 billion.

• Standalone revenue from operations for Q2 FY26: INR 28.7 billion, down from INR 29.5 billion in Q2 FY25; standalone net profit for Q2 FY26: INR 11.6 billion, up from INR 7.9 billion in Q2 FY25.

• Consolidated revenue from operations for Q2 FY26: INR 61.2 billion, up from INR 52.4 billion in Q2 FY25; consolidated net profit for Q2 FY26: INR 12.6 billion, up from INR 9.1 billion in Q2 FY25.

Outlook and guidance

• On track to achieve targeted top-line growth and profitability for FY26, with guidance for 25+ product launches in the US and operating margin guidance of 26%+ for the year.

• Preparing to file NDA for Saroglitazar Magnesium with USFDA in Q4 FY26 after positive Phase 2/3 results; regulatory approval received to initiate Phase II clinical trials of Bivalent Typhoid Conjugate Vaccine in India.

• Board and management did not provide explicit forward-looking guidance in the disclosed materials.